FRFlorian J. Raabe

Florian J. Raabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Florian J. Raabe has a total of 234 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Retinal biomarker assessments in psychiatric disorders: perspective and roadmap from a data and methods sharing initiative

    by Cemal Demirlek, Ali S. Raza, Finn Rabe, Florian J. Raabe, Kaitlyn Kaiser, Erik Velez-Perez, Daman P. Dhunna, Chelsea Kiely, Steve Silverstein, Halide Bilge Turkozer, et al.

  • Open Access

    Excitation-Inhibition Balance in Schizophrenia Spectrum Disorders: EEG Criticality Reflects Frontal Metabolites and a Potential Compensatory Mechanism

    by Genc Hasanaj, Marcel S. Kallweit, Berkhan Karslı, Verena Meisinger, Emanuel Boudriot, Lukas Roell, Julian Melcher, Gizem Vural, Enrico Schulz, Nicole Klimas, et al.

    Background The excitation-inhibition (E-I) balance is essential for normal brain functioning, while deviations from this balance have been implicated in several psychiatric disorders. However, the extent to which electroencephalography (EEG) and proton magnetic resonance spectroscopy (1H-MRS) E-I markers are altered in schizophrenia spectrum disorders (SSD), how they converge across modalities, and how they relate to cognitive performance and clinical symptoms remain insufficiently characterized. Methods We recruited 111 healthy controls (HC) and 113 individuals with SSD. All participants underwent resting-state EEG and 1H-MRS. Metabolites were measured either in the anterior cingulate cortex (ACC; NSSD = 63, NHC = 58) or in the left dorsolateral prefrontal cortex (lDLPFC; NSSD = 50, NHC = 53), from which gamma-aminobutyric acid (GABA), glutamate + glutamine (Glx), and the Glx/GABA ratio were extracted. Extracted EEG E-I markers included oscillatory activity, aperiodic activity, functional E-I, microstates, multiscale entropy, and neuronal avalanche criticality. Results MRS results showed no group differences in GABA, Glx, or the Glx/GABA ratio. In contrast, most EEG-derived E-I markers indicated increased cortical inhibition in SSD, including steeper aperiodic exponents, prolonged microstate durations, and greater prevalence of subcritical states. However, functional E-I showed a divergent pattern, suggesting balanced dynamics in SSD and relatively inhibition-weighted dynamics in HC. Across groups, higher ACC and lDLPFC GABA predicted a lower kappa index, whereas a higher lDLPFC Glx/GABA ratio was associated with a higher kappa index. In SSD, reduced avalanche criticality was associated with better cognition and less severe symptoms. Conclusion Several EEG-derived E-I proxies, but not MRS measures, indicate an increased cortical inhibition in SSD. Criticality indices best capture frontal neurochemical metabolites and improvements in clinical symptoms, potentially reflecting inhibitory compensation mechanisms in SSD.

  • Top Cited Papers
    Open Access

    Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in Schizophrenia

    by Florian J. Raabe, David Popovic, Clara Vetter, Laura E. Fischer, Genc Hasanaj, Berkhan Karslı, Tim J. Schäfer, Valeria Almeida, Alessia Atella, Miriam Gagliardi, et al.

    Importance: While growing evidence implicates synaptic dysfunction as a key pathophysiological mechanism in cognitive impairments in schizophrenia (SCZ), it remains unknown how individual alterations in synaptic connectivity translate into corresponding neural circuit dysfunction and cognitive deficits. Objective: To test whether genetically driven variability in excitatory neurons’ transcriptome and synapse density in patient-derived neurons in vitro explain individual changes in cortical morphology, electrophysiology, and cognitive impairments in vivo. Design, Setting, and Participants: This multimodal case-control study integrated deep clinical phenotyping (magnetic resonance imaging, electroencephalography, and cognitive assessments) across 2 independent cohorts with schizophrenia and healthy controls (N = 461) with donor-matched induced pluripotent stem cell (iPSC)–derived neurons (n = 80). Machine learning, transcriptome imputation, and reverse dynamic causal modeling were applied to link cellular and systems-level phenotypes. Data were collected between September 16, 2014, and November 10, 2023, and analyzed from January 2022 to January 2026. Main Outcomes and Measures: The primary outcome was associations between cellular phenotypes (gene expression, synapse density) and individual-level brain structure, electrophysiology, and cognition. Results: This multiscale translational framework was implemented in 461 individuals with SCZ and healthy controls across 2 independent cohorts. In both cohorts (cohort 1 [C1]: mean [SD] age: 35.1 [11.6] years; 46 female participants [31.1%]; cohort 2 [C2]: mean [SD] age, 36.9 [11.7] years; 140 female participants [44.57%]), cognitive impairments in SCZ were associated with specific gray matter volume reductions across multiple brain regions, in particular the right dorsolateral prefrontal cortex, as well as disturbed electrophysiological activity in the gamma band. Importantly, the individual-level differences in the genetically driven neuronal gene expression patterns and synapse density in vitro predicted the macro-scale alterations of brain structural (C1: r = 0.39; 95% CI, 0.21-0.55; P < .001; iPSC: r = 0.31; 95% CI, −0.07 to 0.60; P = .049; C2: r = 0.23; 95% CI, 0.07-0.37; P = .003), electrophysiological (theta: r = 0.19; 95% CI, 0.04-0.32; P = .05; gamma1: r = 0.17; 95% CI, 0.028-0.31; P = .005; gamma2: r = 0.22; 95% CI, 0.07-0.35; P < .001), and cognitive (C1: r = 0.76; 95% CI, 0.66-0.83; P < .001; iPSC: r = 0.77; 95% CI, 0.57-0.89; P < .001; C2: r = 0.17; 95% CI, 0.02-0.32; P = .02) phenotypes in vivo, providing a mechanistic link from synapse deficits to cognitive impairments in SCZ. Conclusions and Relevance: These findings establish a patient-specific link between genetically driven alterations in gene expression, synaptic dysfunction, and large-scale brain and cognitive phenotypes in SCZ. This multiscale framework provides a foundation for mechanism-based stratification and precision target identification for cognitive impairment.


  • Open Access

    The link between GABA levels and P300 abnormalities in schizophrenia spectrum disorders: regional and symptom-based insights

    by Berkhan Karslı, Verena Meisinger, Genc Hasanaj, Marcel S. Kallweit, Fanny Dengl, Gizem Vural, Julian Melcher, Maxim Korman, Nicole Klimas, Susanne Schmölz, et al.

    According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms, particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and may contribute to P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P3b subcomponent amplitudes and latencies, cognition, and symptom severity in SSD. In total, 107 patients and 107 healthy controls (HC) were included in the study, with the exact numbers varying across specific analyses. We grouped patients into higher (SSD+, N = 41) and lower (SSD−, N = 65) symptom severity clusters based on PANSS total scores. P3b amplitudes were lower in SSD patients than HC at central and parietal sites. SSD+ exhibited widespread P3b amplitude reductions, significant at parietal and trend-level at central and frontal regions, while SSD− showed a trend-level amplitude reduction limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P3b amplitudes at central and parietal sites within SSD− and overall SSD group. Although P3b amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P3b associations. Our findings suggest P3b amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher illness severity, and that enhanced lDLPFC GABA may contribute to offsetting these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns associated with cognitive dysfunction in SSD.


  • Open Access

    Estimating Accelerated Retinal Decline in Mental Health Disorders Through Normative Modeling

    by Foivos Georgiadis, Finn Rabe, Nils Kallen, Giacomo Cecere, Victoria Edkins, Daniel Barthelmes, Amber Roguski, Daniel J Smith, Emanuel Boudriot, Florian J Raabe, et al.

    Background and Hypothesis: Several studies have found that retinal tissue is thinner in people with mental health disorders than in healthy controls (HC). However, most research has examined group-level differences and has therefore inadequately accounted for normative biological heterogeneity. A focus on single disorders has also made transdiagnostic comparisons challenging. We used normative modeling to estimate age-related decline of the human retina (and its expected variation) and compared it to the decline seen in schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). We hypothesized accelerated retinal decline in mental health disorders compared to controls, with SZ being most affected, followed by BD, then MDD. Study Design: Using UK Biobank data, we estimated age-related retinal decline (age range: 40-70) in HC (n = 51 225) for total macular thickness (including coronal subfields) and its 8 segmented sublayers. We then compared the decline in SZ (n = 170), BD (n = 263), and MDD (n = 95) to the normative decline in HC. Adjustments were made for known confounding variables. Study Results: For HC, the pattern of estimated age-related decline for retinal thickness was curve-like and generally more pronounced in males compared to females. Individuals with a mental health disorder showed more pronounced retinal thinning; this effect was greatest in SZ and disorder-specific macular subfields. There was also an enrichment of individuals with extremely low (infranormal) values in the patient group. Conclusion: Our findings suggest that major mental health disorders, particularly SZ, involve accelerated retinal thinning, detectable with normative modeling.


  • Open Access

    Periodic and Aperiodic Alterations of Resting‐State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights

    by Genc Hasanaj, Iris Jaeger, Berkhan Karsli, Enrico Schulz, Emanuel Boudriot, Lukas Roell, Maxim Korman, Marcel S. Kallweit, Fanny Dengl, Nicole Klimas, et al.

    Schizophrenia spectrum disorders (SSD) are marked by cognitive deficits and clinical symptoms linked to disrupted neural oscillations. While changes in spectral power are well documented in SSD, many studies have not clearly separated rhythmic (periodic) from the nonrhythmic (aperiodic) brain activity. This study examined both periodic and aperiodic resting‐state EEG components in SSD, recorded from 152 healthy controls and 97 SSD participants. EEG features (periodic power, bandwidth, center frequency; aperiodic exponent and offset) were extracted from global scalp averages and frontoinsular regions, including the dorsal anterior cingulate cortex (dACC), right anterior insula (R‐INS), and left anterior insula (L‐INS). At the scalp level, SSD individuals exhibited a global increase in theta power, along with a decreased alpha center frequency. Aperiodic activity showed increased exponent and offset in SSD. In frontoinsular regions, increased theta power was observed in the dACC, R‐INS, and L‐INS, along with lower alpha center frequency in L‐INS. No significant differences were found for aperiodic activity in these regions. Increased frontoinsular theta power, especially in the dACC, was associated with worse cognitive performance, particularly global cognition and working memory. These findings highlight the importance of separating periodic and aperiodic EEG activity in SSD, suggesting that periodic alterations, particularly in frontoinsular theta oscillations, may underlie cognitive dysfunction in SSD.


  • Open Access

    Clinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study

    by Vladislav Yakimov, Lara Neuwinger, Madeleine M. Weber, Maximilian Brantl, Isabel Maurus, Jana Sautner, Miriam John, Berkhan Karslı, Genc Hasanaj, Anne Bungard, et al.

    Schizophrenia spectrum disorders (SSDs) exhibit a marked heterogeneity in clinical course and treatment outcomes. Some individuals achieve remission and recovery, whereas others experience repeated relapses and progressive deterioration in psychosocial functioning. This variability underscores the unmet clinical need for prognostic biomarkers to predict treatment outcomes and guide personalized care. Deep phenotyping with multimodal data integration holds promise for understanding this complexity and delivering clinically relevant predictive models of treatment response in SSDs. To address this need, we initiated the Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR) study, a prospective, naturalistic, longitudinal observational study integrating comprehensive multimodal assessments. These include clinical phenotyping, magnetic resonance imaging (MRI), electroencephalography (EEG), retinal imaging, and extensive sampling of blood and cerebrospinal fluid (CSF) for multi-omics profiling. The study aims to externally validate promising biomarker candidates and elucidate the pathophysiological mechanisms underlying treatment outcomes. This innovative deep phenotyping framework integrates data across multiple critical domains, enabling external validation of potential biomarkers and the discovery of novel ones. Ultimately, the CDP-STAR study aims to yield mechanistic insights that advance precision psychiatry and inform clinical decision-making in SSDs.


  • Open Access

    iPSC-modelling reveals genetic associations and morphological alterations of oligodendrocytes in schizophrenia

    by Man-Hsin Chang, Jan Benedikt Waldeck, Marius Stephan, Nirmal Kannaiyan, Valéria de Almeida, Emanuel Boudriot, Temmuz Karali, Lukas Röll, Laura Fischer, Damianos Demetriou, et al.

    There is strong evidence for a genetically driven neuronal contribution in schizophrenia (SCZ). Although imaging and postmortem studies also provide evidence for white matter alterations with implications of the oligodendroglial lineage in SCZ, it is unclear whether these disturbances are a secondary consequence of neuronal deficits or also, at least in parts, genetically driven and cell-autonomous. Using human induced pluripotent stem cells (hiPSCs) in combination with gene set enrichment analysis, we investigated the cellular impact of SCZ genetics on the oligodendroglial lineage. We performed unsupervised clustering analysis of hiPSC-differentiated neural cells including oligodendrocytes (iOLs) and their precursor cells (iOPCs) with corresponding human postmortem cell types from single-cell RNA sequencing (scRNAseq) data and conducted a comparative gene set enrichment analysis. Subsequently, we stratified individuals based on white matter alteration using diffusion tensor imaging (DTI) within a translational cohort (N = 112) and then explored the cellular effects of SCZ risk with hiPSC modelling in a subset of SCZ patients (N = 8) with disturbed white matter integrity and unaffected healthy controls (N = 7). hiPSC-iOPCs/iOLs expression profiles strongly correlated with human postmortem OPCs/OLs based on scRNAseq, and their transcriptional signatures were highly enriched in the genetic associations of SCZ. The cellular assessment of patient-derived iOPCs/iOLs revealed morphological alterations, including significantly increased branch length and elevated junction number in mature iOLs from SCZ. Moreover, transcriptomic profiling revealed a dysregulation in oligodendroglial cell signaling and proliferation. In sum, hiPSC-modelling shows an impact of SCZ genetics on dedicated features of the oligodendroglial lineage.


  • Open Access

    Relationship between blood-cerebrospinal fluid barrier integrity, cardiometabolic, and inflammatory factors in schizophrenia-spectrum disorders

    by Vladislav Yakimov, Iris Jäger, Lukas Roell, Emanuel Boudriot, Verena Meisinger, Mattia Campana, Lenka Krčmář, Sean Halstead, Nicola Warren, Dan Siskind, et al.


  • Open Access

    Cerebrospinal fluid proteomics reveals synaptic and immune dysregulation in treatment-resistant schizophrenia

    by Laura E. Fischer, Michael G. Gottschalk, Lars U. G. Reitz, Joanna Moussiopoulou, Nikolaos Koutsouleris, Vladislav Yakimov, Emanuel Boudriot, Sophie Seeburger, Tengjia Jiang, Johanna Weiske, et al.

    IMPORTANCE: Treatment-resistant schizophrenia (TRS) affects around one-third of individuals with schizophrenia and is associated with substantial morbidity, mortality, and healthcare burden. Despite its impact, the pathophysiology of TRS remains poorly understood, and no validated biomarkers exist to predict or stratify treatment resistance and identify patients who may benefit from earlier second-line interventions. OBJECTIVE: To identify cerebrospinal fluid protein signatures associated with treatment-resistant schizophrenia using high-throughput immune-based proteomic profiling, and to characterize their biological relevance and evaluate their predictive potential. DESIGN, SETTING AND PARTICIPANTS: This cross-sectional study analyzed cerebrospinal fluid samples, collected between 2001 and 2024 during routine clinical practice in two centers, of 64 patients with treatment-resistant schizophrenia, and 84 sex-, age-, and center-matched non-treatment-resistant patients. Proteomic profiling was performed using Olink Explore HT, a highly sensitive, multiplexed proximity extension assay capable of quantifying up to 5,416 proteins. Univariate differential expression analysis, Gene Set Enrichment Analysis, and Support Vector Machine modelling were conducted to identify treatment-resistant schizophrenia-associated proteins, explore underlying biological mechanisms, and uncover predictive biomarker signatures. MAIN OUTCOMES AND MEASURES: Differentially expressed proteins, associated functional pathway enrichments, and classification performance of predictive models based on cerebrospinal fluid proteomics. RESULTS: 1,839 protein assays passed detection threshold in cerebrospinal fluid proteomic analysis using Olink Explore HT. 98 proteins were differentially expressed in individuals with treatment-resistant schizophrenia and 95 displayed consistent fold changes across both study centers. Gene Set Enrichment Analysis revealed that upregulated proteins were linked to immune-related pathways, while downregulated proteins were predominantly enriched in synapse-related processes, including glutamatergic signaling. Multivariate support vector machine modelling identified 64 proteins predictive of treatment-resistant schizophrenia, of which 63 overlapped with the differentially expressed proteins. CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid proteomic profiling indicates activation of immune-related processes and synaptic dysfunction in treatment-resistant schizophrenia, supporting the hypothesis that it represents a neurobiologically distinct subtype of the disorder. The identified candidate biomarker signature may support the development of liquid biopsy-based diagnostic tools and guide targeted treatment strategies. Key Points: Question: Are there proteomic alterations in the cerebrospinal fluid (CSF) of patients with treatment-resistant schizophrenia (TRS)? Findings: Unbiased CSF proteomics identified 98 proteins dysregulated in TRS, implicating pathways of neuroinflammation and synaptic dysfunction. Machine-Learning Validation pinpointed protein features with the strongest predictive value for TRS, of which 63 overlapped with the differentially expressed proteins. Meaning: The intersection of univariate and multivariate results yields a prioritized panel of protein biomarkers with potential to distinguish TRS patients from those responsive to first-line antipsychotic therapy. The identified CSF-based proteomic signature reveals immune and synaptic alterations in TRS and may pave the way for early diagnostic tools and targeted interventions to alter its disease-course.